All Oncology News

James Harding, MD, highlighted current and emerging areas of research in biliary tract cancer, including key contributions from TOPAZ-1 and the phase 3 SWOG 1815 trial, the development of immunotherapy and chemotherapy combinations, and continued efforts to utilize personalized medicine in clinical practice.

Rohit Kumar, MD, discusses the benefits of TKI/immunotherapy doublets in renal cell carcinoma, unmet needs regarding future research with triplet therapies in the frontline setting, and how hypoxia inducible factor inhibitors may play a role in the treatment of patients who have progressed on prior TKI/immunotherapy combinations.

Matthew Brunner, MD, discusses how key patient factors, the use of advanced imaging modalities, and the relationship between community and academic centers influence treatment approaches in relapsed/refractory multiple myeloma.

In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments.

The FDA has placed a partial clinical hold on the phase 1/2 VELA trial due to visual adverse effects observed in select patients who received the investigational treatment BLU-222.

The National Comprehensive Cancer Network has partnered with the American Cancer Society Cancer Action Network and the National Minority Quality Forum to launch the new Health Equity Report Card pilot program to address structural and interpersonal bigotry that results in disparities in cancer care and outcomes.

Idecabtagene vicleucel improved progression-free survival compared with standard combination regimens in patients with relapsed/refractory multiple myeloma after 2 to 4 prior lines of therapy and who were refractory to their last regimen, according to results from the phase 3 KarMMa-3 trial.

An international research group, led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has developed a new machine learning algorithm that can combine large datasets from multiple sources to pinpoint kinases and potentially target them for treatment.

The combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carcinoma.

Although emerging strategies are expanding options for treating patients with early-stage non–small cell lung cancer, stage IIIB disease continues to pose challenges. A multimodality approach may help overcome current barriers to care.

Scott Kopetz, MD, discussed the key objectives of the phase 3 BREAKWATER trial being done in patients with BRAF V600E–mutated mCRC, the recently reported safety and efficacy data observed with encorafenib plus cetuximab and chemotherapy, and the importance of conducting biomarker research to further personalize treatment in these patients.

In an 8 to 5 vote, the FDA’s ODAC voted that data from two proposed single-arm trials will provide adequate means of characterizing the risk-benefit profile of dostarlimab for the treatment of patients with dMMR/MSI-H locally advanced rectal cancer.

The FDA has granted a regular approval to dostarlimab-gxly (Jemperli) for adult patients with mismatch repair–deficient, recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.

Emma L. Barber, MD, emphasized the importance of the ongoing phase 3 PORTEC-4a trial, which is investigating the role of molecular risk profiles in determining whether patients with endometrial cancer should receive no adjuvant therapy, vaginal brachytherapy, or external beam radiotherapy.

Investigators in the phase 2 SWOG S2107 trial are evaluating encorafenib plus cetuximab and nivolumab for patients with previously treated, microsatellite stable, unresectable, or metastatic colorectal cancer harboring a BRAF V600E mutation.

Elevation Oncology is pausing development of the human anti–HER3 IgG2 monoclonal antibody seribantumab, along with the phase 2 CRESTONE trial investigating the agent, in patients with advanced solid tumors harboring NRG1 fusions.

Multiple teams working inside the Georgia Cancer Center at the Medical College of Georgia at Augusta University are committed to closing care gaps across Georgia.

The CAR T-cell therapy brexucabtagene autoleucel produced a median overall survival of 26 months in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Alfred L. Garfall, MD, discusses the durability of responses teclistamab elicited in the MajesTEC-1 trial and how this agent will change the treatment regimen for relapsed/refractory multiple myeloma.

Roy S. Herbst, MD, PhD, discussed the data that supported the FDA approval of adjuvant pembrolizumab in patients with non–small cell lung cancer, highlighted the implications of the approval for the paradigm, and outlined further research opportunities.

Oral progesterone receptor antagonist onapristone extended release in combination with anastrozole induced a confirmed partial response in 2 patients with hormone receptor–positive metastatic endometrial cancer.

Bartosz Chmielowski, MD, discusses the rationale for IGNYTE, the unique mechanism of action of RP1, and how melanoma research is seeking to determine treatments for patients based on their individual resistance mechanisms.

The FDA has granted an orphan drug designation to ezurpimtrostat, a PPT-1 inhibitor for the treatment of patients with hepatocellular carcinoma.

Caspian Oliai, MD, discusses how treatment with Orca-T demonstrated a reduction in graft-vs-host disease and non-relapse mortality rates, while also producing higher than expected graft-vs-leukemia and graft-vs-infection effects, in patients with hematologic cancers at more than 1 year of follow-up.

Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.

For decades, resection of the primary tumor, either up front or after neoadjuvant therapy, has remained the standard of care for patients with early-stage (stage I-III) colorectal cancer. Recently, a plethora of data have been published that might change the current surgery-centered paradigm.

Despite the favorable comments and interest in clinical trials, the objective fact is that a distressingly low percentage of patients with cancer, in the range of 2% to 4%, are enrolled in clinical investigative efforts.

The selective small molecule MDM2 inhibitor milademetan administered at an intermittent dosing schedule was tolerable and showed early efficacy in patients with advanced cancers, according to findings from a phase 1 study.

Lamanna discussed key efficacy and safety data with zanubrutinib from the SEQUOIA and ALPINE trials, the advantages of zanubrutinib compared with previous therapeutic options, and how the approval of the agent will affect the use of next-generation BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma .

To continue making progress in lung cancer treatment, investigators must keep pushing the science in new directions even as immunotherapy becomes more available in earlier lines.